New Paxlovid Data Show Limited Efficacy

Pfizer’s COVID-19 drug Paxlovid (nirmatrelvir, ritonavir) has shown limited efficacy in reducing the risks of symptoms for standard-risk patients in a phase 2/3 study.

The FDA authorized the drug for emergency use for high-risk groups based on its efficacy in reducing hospitalizations and deaths in that group.

Due to a very low rate of hospitalization or death observed in the standard-risk patient population, Pfizer has decided to end enrollment in the study and include the available data in a planned New Drug Application (NDA) submission to the FDA this month to support the use of Paxlovid in individuals at high risk of progression to severe illness.